With 0.64 million shares changed hands, the volume of the stock remained lighter than its average volume of 0.66 million shares. During the session, the Biotechnology company that operates in wider Healthcare sector, reached to the highest price of $2.32 whereas the lowest price it dropped to was $2.15. The 52-week range on FBIO shows that it touched its highest point at $4.43 and its lowest point at $1.36 during that stretch. It currently has a 1-year price target of $15.00. Beta for the stock currently stands at 1.67.
Price Performance and Earnings:
Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of FBIO was up-trending over the past week, with a rise of 30.36%, but this was up by 15.26% over a month. Three-month performance surged to 17.11% while six-month performance rose 19.02%. The stock gained 0.92% in the past year, while it has lost -27.24% so far this year. A look at the trailing 12-month EPS for FBIO yields -3.27 with Next year EPS estimates of -1.48. For the next quarter, that number is -0.75. This implies an EPS growth rate of 58.60% for this year and 57.70% for next year. EPS is expected to grow by 25.50% annually over the next five years; however, over the past five years, the company experienced an annual growth rate of 22.28%.
Float and Shares Shorts:
At present, 27.58 million FBIO shares are outstanding with a float of 21.92 million shares on hand for trading. On 2024-10-31, short shares totaled 2.62 million, which was 951.0 higher than short shares on 1727654400. In addition to Dr. Lindsay Allan Rosenwald as the firm’s Executive Chairman, President & CEO, Mr. David Jin serves as its CFO & Head of Corporate Development.
Institutional Ownership:
Through their ownership of 0.15782 of FBIO’s outstanding shares, institutional investors have minority control over the company.
An Overview of Recent Financials:
Understanding a company as a customer does not mean you will understand it as an investor. The wise investor uses quantitative research to analyze metrics such as revenue, net income, and earnings. In its fiscal quarter reported on 2024-06-30, FBIO reported revenue of $14629000.0 and operating income of -$22095000.0. The EBITDA in the recently reported quarter was -$21085000.0 and diluted EPS was -$0.76.
Analysts Ratings:
Reading analyst opinions is an effective way to decide where to invest, and there are several opinions available for FBIO since 3 analysts follow the stock currently. There are 2 analysts who recommend BUY ratings, while 0 suggest SELL ratings. Of the remaining analysts, 0 believe that the stock is worth HOLDING, 0 give it an OVERWEIGHT rating, and 1 thinks that it’s UNDERWEIGHT. In the same way, a target price assigned to a stock can also reveal much about its potential. With FBIO analysts setting a high price target of 24.0 and a low target of 4.0, the average target price over the next 12 months is 14.33333. Based on these targets, FBIO could surge 995.89% to reach the target high and rise by 82.65% to reach the target low. Reaching the average price target will result in a growth of 554.49% from current levels.
Analysts have provided yearly estimates in a range of -$2.59233 being high and -$4.42088 being low. For FBIO, this leads to a yearly average estimate of -$3.50667. The surprise factor in the prior quarter was -$1.22. Based on analyst estimates, the high estimate for the next quarter is $0 and the low estimate is $0. The average estimate for the next quarter is thus $0.
